Potential therapeutic targets in obstructive sleep apnoea.
Obstructive sleep apnoea (OSA) is a disease of ever-increasing importance due to its association with multiple impairments and rising prevalence in an increasingly susceptible demographic. The syndrome is linked with loud snoring, disrupted sleep and observed apnoeas. Serious co-morbidities associated with OSA appear to be reversed by continuous positive airway pressure (CPAP) treatment; however, CPAP is variably tolerated leaving many patients untreated and emphasising the need for alternative treatments. Virtually all OSA patients have airways that are anatomically vulnerable to collapse, but numerous pathophysiological factors underlie when and how OSA is manifested. This review describes how the complexity of OSA requires multiple treatment approaches that are individually targeted. This approach may take the form of more specific diagnoses in terms of the mechanisms underlying OSA as well as rational pharmacological treatment directed toward such disparate ends as arousal threshold and ventilatory control/chemosensitivity, and mechanical treatment in the form of surgery and augmentation of lung volumes.
Saboisky
Julian P
JP
Brigham and Women's Hospital, Harvard Medical School, Division of Sleep Medicine, 221 Longwood Avenue, Boston, Massachusetts 02115, USA. JSABOISKY@partners.org
Chamberlin
Nancy L
NL
Malhotra
Atul
A
D000818:Animals; D002986:Clinical Trials as Topic; D045422:Continuous Positive Airway Pressure / Q000009:adverse effects / Q000379:methods*; D016503:Drug Delivery Systems; D006801:Humans; D008176:Lung Volume Measurements; D015656:Respiratory Mechanics; D020181:Sleep Apnea, Obstructive / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*